*** For details on how to be removed from this list visit the ***
*** CCP4 home page http://www.ccp4.ac.uk ***
We will hold a "traditional" poster session at the Autumn
eCheminfo Meeting "Latest Advances in Drug Discovery
Design & Planning Methods" which takes place 16-19 October
2006, Bryn Mawr, Philadelphia, USA
Poster Abstracts (of ca. 300 words) with Title,
Institution, Address, Authors and Contact Information
should be submitted for review to eCheminfo [at]
douglasconnect.com Poster Abstract submission deadline is
31 August 2006 although earlier submissions are
encouraged.
Posters may be on any topic of relevance to drug discovery
and development but should include new or recent novel
research, application or innovation.
The meeting themes include Structure-based Drug Design,
Screening & Docking, Cheminformatics & Modeling supporting
Medicinal Chemistry, Pharmacophores, Metabolomics, Quantum
Biochemistry, Knowledge Management, Electronic Lab
Notebooks, Critical Path Innovation in Drug Development,
Biomarkers, Predictive Toxicology & ADME.
The poster session is planned to take place on the evening
of Wednesday October 18th and will be accompanied by a bbq
on campus. If we have too many posters for viewing that
evening, we will also run a second evening on Monday
October 16th.
Open seminars and workshops on Electronic Lab Notebooks
and a Knowledge Cafe on knowledge management in R&D will
take place the afternoon & evening of October 17th. (Open
for proposals through 21 July, please contact barry.hardy
[at] douglasconnect.com to discuss program proposals).
The preliminary main conference and workshop program and
schedule for the meeting is available at:
http://www.echeminfo.com/COMTY_conferences/
Registration enquiries can be directed to eCheminfo [at]
douglasconnect.com
best regards
Barry Hardy
eCheminfo Community of Practice
Douglas Connect
Baermeggenweg 14, Zeiningen
CH-4314, Switzerland
Tel: +41 61 851 0170
Confirmed Speakers at the Bryn Mawr meeting include:
Frank Hollinger (Locus Pharmaceuticals), Erin Duffy
(Rib-X), Mike Malamas (Wyeth), Debananda Das (NCI), Max
Cummings (Johnson & Johnson PR&D), Lance Westerhoff
(QuantumBio), Jose Duca (Schering-Plough), Osman Guner
(Turquoise Consulting), Hege Beard (Schrodinger), Stan
Young (NISS), John Irwin (UCSF), William Douglas Figg
(NCI), Darryl Reid (SimBioSys), Gregory Warren
(GlaxoSmithKline), Deepak Bandyopadhyay (Johnson & Johnson
PR&D), Paul Hawkins (OpenEye), Chris Cooper (BMS), James
Arnold (Astra-Zeneca), Phil Edwards (Astra-Zeneca), Pete
Connolly (Johnson & Johnson PR&D), Dimitris Agrafiotis
(Johnson & Johnson PRD), Jim Wikel (Coalesix), Tudor Oprea
(Univ. New Mexico), Alex Tropsha (UNC), Curt Breneman
(RPI), Sanji Bhal (ACD/Labs), Michael Bolger (Simulations
Plus), Bob Clark (Tripos), Gilles Klopman (Multicase),
Navita Mallalieu (Roche Pharmaceuticals), Zentam
Tsuchihashi (BMS), Peter Henstock (Pfizer), Darius Dziuda
(Multivariate bioMarkers Discovery), Keith Elliston
(Genstruct), Michael Liebman (Windber Research Institute),
Jonathan Sheldon (InforSense), Duane Shugars (Concentia
Digital), Jian Wang (Biofortis), Peter Gates (Johnson &
Johnson PR&D), Barry Hardy (Douglas Connect), Dennis
Underwood (Praxeon), Jeff Spitzner (Rescentris), David
Mosenkis (Spotfire), Joel Hoffman (Insightful
Corporation), Delia Wolf (Harvard Medical School), Craig
Liddell (Realtime Science), Joseph Bitran (Enterprizer),
Alvin Berger (Metabolon), Gregory Banik (Bio-RAD), George
Harrigan (Monsanto), Rick Beger (NCTR, FDA), Don Robertson
(Pfizer), Teresa Garret (Duke University), Laszlo Boros
(SIDMAP), Bruce Kristal (Cornell University), Andrew Lane
(JG Brown Cancer Center, U. Louisville), Oliver Fiehn (UC
Davis Genome Center), Susan Connor (Glaxo SmithKline),
Michael Jones (Novartis)
